Reported about 16 hours ago
Bristol Myers Squibb and Bain Capital have announced the formation of a new independent company dedicated to developing immunology drugs, supported by Bain's $300 million investment. This venture will focus on five experimental drugs, including treatments for lupus and psoriasis, allowing Bristol Myers to concentrate on broader immunology research while still benefiting from the success of these promising treatments.
Source: YAHOO